NGSP and the College of American Pathologists (CAP), 2020
The American Diabetes Association (ADA) recommends that HbA1c tests should be performed using a method that is certified by NGSP. Participation in a proficiency testing survey (external quality assessment), such as the CAP GH5 fresh whole blood HbA1c program, allows individual laboratories to compare their performance against peer groups and against the target values assigned by NGSP.
The survey data from the first CAP survey in 2020, GH-5a, show absolute mean bias for each method group analyzed, which ranged from 0.00 to 0.26% HbA1c. There were no methods with a bias >0.30% HbA1c. Method-specific, between-laboratory coefficient of variation (CV) ranged from 1.0 to 4.2%. There were six methods with CVs ≤2% for 5 out of 5 samples and approximately 72% of laboratories are using methods with between-lab CVs <3% at all five (or all 3) HbA1c levels.
The CAP GH-5a 2020 Summary and all CAP GH5 proficiency testing data can be accessed here.
&cópia de; 2022 Abbott. Todos os direitos reservados. Todas as marcas comerciais mencionadas são marcas comerciais do grupo de empresas Abbott ou de seus respectivos proprietários.
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessmentenAcesse agora
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney diseaseenAcesse agora